COMPANY PROFILE

Creyon Bio

Transforming nucleic acid medicine with precise, on-demand oligonucleotide therapeutics for safe and effective gene-centric therapies

Carlsbad, United StatesFounded 2019Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Creyon Bio

Creyon Bio, Inc. is a biotechnology company revolutionizing the drug development process by focusing on nucleic acid medicine. The company serves pharmaceutical and biotech clients, operating in the drug discovery and development market. Creyon Bio employs a modular approach to create on-demand oligonucleotide therapeutics, which are short DNA or RNA molecules designed to treat specific genetic conditions. This approach significantly reduces the cost and time required to develop new medicines, whether for rare diseases affecting a single patient or widespread conditions impacting millions. The company leverages powerful, purpose-built data sets to drive the creation of machine learning models, enabling the engineering of Medicines OBMs (Oligonucleotide-Based Medicines) with minimal off-target effects. This ensures high precision, efficacy, and safety in gene-centric therapies. Creyon Bio generates revenue through partnerships and collaborations with pharmaceutical companies, offering its advanced drug engineering capabilities to accelerate their drug development pipelines.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Carlsbad, United States
Employees: 27
Open positions: None listed
Dealroom signal: 59.2/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Precision Medicine, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Mar 2022	$40M	$160M	Casdin Capital · Alexandria Venture Investments · Lux Capital · DCVC	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Creyon Bio website traffic

Latest recorded traffic for Creyon Bio is 2.3K monthly website visits, up 130% over the last three months. Creyon Bio's team declined 40% over the past year.

Latest monthly visits2.3K 3-month web change+130% 1-year team growth-40%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CLClovernaRNA Targeted Drug Discovery Platform	Kurashiki, Japan	Operational	2	$1.1M	—
ASAlgorithm SciencesPrecision medicines and delivery systems for rare diseases	New York City, United States	Operational
PBPath BioAnalyticsAn Advanced assays accelerating the discovery, development and use of new medications for respiratory disease	Chapel Hill, United States	Operational
CPCircumvent PharmaceuticalsSeeking to address the significant unmet need of neurodegenerative disease patients	Portland, United States	Operational
BABasgenbioVaszenio is a bio-vitator based on artificial intelligence that offers more than health value	Seoul, South Korea	Operational
INInocrasProviding a comprehensive view of a patient's entire genetic profile through WGS analysis and interpretations	United States	Operational
QTQED TherapeuticsA biotechnology company focused on precision medicine for FGFR-driven disorders	Palo Alto, United States	Operational
GEGenomeupAI-powered solutions for genetic analysis and clinical decisions	Rome, Italy	Operational